HRP940311B1 - New peptide derivatives - Google Patents

New peptide derivatives

Info

Publication number
HRP940311B1
HRP940311B1 HR940311A HRP940311A HRP940311B1 HR P940311 B1 HRP940311 B1 HR P940311B1 HR 940311 A HR940311 A HR 940311A HR P940311 A HRP940311 A HR P940311A HR P940311 B1 HRP940311 B1 HR P940311B1
Authority
HR
Croatia
Prior art keywords
peptide derivatives
new peptide
new
therapy
compound
Prior art date
Application number
HR940311A
Other languages
English (en)
Inventor
Karl Thomas Antonsson
Ruth Elvy Bylund
Nils David Gustafsson
Nils Olov Ingemar Nilsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP940311A2 publication Critical patent/HRP940311A2/hr
Publication of HRP940311B1 publication Critical patent/HRP940311B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
HR940311A 1993-06-03 1994-05-17 New peptide derivatives HRP940311B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301916A SE9301916D0 (sv) 1993-06-03 1993-06-03 New peptides derivatives

Publications (2)

Publication Number Publication Date
HRP940311A2 HRP940311A2 (en) 1996-10-31
HRP940311B1 true HRP940311B1 (en) 2002-02-28

Family

ID=20390165

Family Applications (1)

Application Number Title Priority Date Filing Date
HR940311A HRP940311B1 (en) 1993-06-03 1994-05-17 New peptide derivatives

Country Status (40)

Country Link
US (4) US5602253A (de)
EP (2) EP0701568B1 (de)
JP (3) JP3205558B2 (de)
KR (1) KR100339456B1 (de)
CN (2) CN1099425C (de)
AT (1) ATE200783T1 (de)
BR (1) BR9406746A (de)
CA (1) CA2162900C (de)
CZ (1) CZ290104B6 (de)
DE (3) DE69427150T2 (de)
DK (1) DK0701568T3 (de)
EE (1) EE03264B1 (de)
EG (1) EG20671A (de)
ES (1) ES2128277T3 (de)
FI (1) FI119812B (de)
GR (1) GR3036258T3 (de)
HK (1) HK1031375A1 (de)
HR (1) HRP940311B1 (de)
HU (2) HU0103039D0 (de)
IL (2) IL109634A (de)
IS (1) IS1805B (de)
LT (1) LT3768B (de)
LU (1) LU91173I2 (de)
MX (1) MX9404114A (de)
MY (1) MY119155A (de)
NL (1) NL300178I2 (de)
NO (2) NO314406B1 (de)
NZ (1) NZ267534A (de)
PL (1) PL181968B1 (de)
PT (1) PT701568E (de)
RS (1) RS49576B (de)
RU (1) RU2142469C1 (de)
SA (1) SA94150051B1 (de)
SE (1) SE9301916D0 (de)
SG (1) SG48013A1 (de)
SI (1) SI0701568T1 (de)
SK (1) SK283150B6 (de)
TW (1) TW403731B (de)
UA (1) UA65518C2 (de)
WO (1) WO1994029336A1 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
SE9900043D0 (sv) * 1999-01-11 1999-01-11 Astra Ab New use
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0724570B1 (de) * 1993-10-21 1999-03-03 G.D. Searle & Co. Amidino-derivate als no-synthetase inhibitoren
JP4561696B2 (ja) * 1994-01-27 2010-10-13 三菱化学株式会社 プロリンアミド誘導体
ZA951618B (en) * 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5602101A (en) * 1994-03-04 1997-02-11 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
CA2143533A1 (en) * 1994-03-04 1995-09-05 Kenneth D. Kurz Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5885967A (en) * 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
IL112795A (en) * 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
US6090786A (en) * 1994-06-10 2000-07-18 Fondatech Benelux N.V. Serine proteases, their activity and their synthetic inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
DE4443390A1 (de) * 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
EA002767B1 (ru) * 1995-02-10 2002-08-29 Басф Акциенгезельшафт Ингибиторы тромбина
CN1198839C (zh) * 1995-02-17 2005-04-27 艾伯特有限及两合公司 作为凝血酶抑制剂的新的二肽脒类
US5914319A (en) * 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5629324A (en) * 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
US5610308A (en) * 1995-05-18 1997-03-11 Bristol-Myers Squibb Company Process for preparing intermediates for thrombin inhibitors
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
KR100445094B1 (ko) 1995-07-26 2005-06-17 미쓰비시 가가꾸 가부시키가이샤 페니실라민아미드유도체
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
TW455580B (en) * 1995-12-09 2001-09-21 Roche Diagnostics Gmbh 3-aminoethyl-N-amidino-2,5-dihyropyrrole-derivatives having arginine mimentic properties and pharmaceutical compositions containing these compounds
GB9526273D0 (en) * 1995-12-21 1996-02-21 Astra Ab New prodrugs
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9600216D0 (sv) * 1996-01-18 1996-01-18 Hans Arne Hansson Styrning av läkningsprocesser
NZ331327A (en) * 1996-02-13 2000-01-28 Akzo Nobel Nv Serine protease inhibitors having an acylguanidine side chain
IL120311A (en) * 1996-03-01 2001-10-31 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
IL120310A (en) * 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
US5811402A (en) * 1996-03-22 1998-09-22 Eli Lilly And Company Antithrombotic diamides
SE9602145D0 (sv) * 1996-05-31 1996-05-31 Astra Ab New improved formulation for treatment of thromboembolism
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
AU3496297A (en) * 1996-06-25 1998-01-14 Eli Lilly And Company Anticoagulant agents
US6200967B1 (en) 1996-06-25 2001-03-13 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
US6756389B2 (en) * 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US5792761A (en) * 1996-08-12 1998-08-11 Merck & Co., Inc. Thrombin inhibitors
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
DE19632773A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
IL121474A0 (en) * 1996-08-23 1998-02-08 Akzo Nobel Nv Thrombin inhibitors
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
US5869487A (en) * 1996-10-24 1999-02-09 Merck & Co., Inc. Pyrido 3,4-B!pyrazines for use as thrombin inhibitors
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
EP1009758B1 (de) * 1997-08-29 2005-06-01 Tularik Limited Meta-benzamidinderivate als serinprotease-inhibitoren
US6740682B2 (en) 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
US6087373A (en) * 1997-09-23 2000-07-11 Merck & Co., Inc. Thrombin inhibitors
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
DE19755682A1 (de) * 1997-12-15 1999-06-17 Knoll Ag Verfahren zur Ermittlung eines Dosierungschemas für Thrombininhibitoren
AU751111B2 (en) 1998-01-26 2002-08-08 Basf Aktiengesellschaft Thrombin inhibitors
JP2002501044A (ja) * 1998-01-26 2002-01-15 ビーエーエスエフ アクチェンゲゼルシャフト カリクレインプロテアーゼ阻害剤としての複素環アミジン
US6417161B1 (en) 1998-04-24 2002-07-09 3-Dimensional Pharmaceuticals, Inc. Amino acid amidinohydrazones, alkoxyguanidines and aminoguanidines as protease inhibitors
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802939D0 (sv) 1998-09-01 1998-09-01 Astra Ab New process
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
EP0987274A1 (de) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Faktor VIIa Inhibitore
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
KR20000047461A (ko) * 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
SE9900070D0 (sv) 1999-01-13 1999-01-13 Astra Ab New use
BR0007453A (pt) 1999-01-13 2001-10-30 Astrazeneca Ab Composto, formulação farmacêutica, uso de umcomposto, método de tratamento de uma condiçãoonde a inibição da trombina é requerida e,processo de preparação de um composto
EP1169338B1 (de) 1999-04-09 2004-11-03 Abbott GmbH & Co. KG Niedermolekulare inhibitoren von komplementproteasen
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
AR023819A1 (es) * 1999-05-03 2002-09-04 Astrazeneca Ab FORMULACIoN FARMACEUTICA, KIT DE PARTES Y UTILIZACION DE DICHA FORMULACION
DE50008187D1 (de) 1999-05-10 2004-11-18 Abbott Gmbh & Co Kg Salze von Thrombininhibitoren
AU5451400A (en) 1999-06-04 2000-12-28 Merck & Co., Inc. Thrombin inhibitors
EP1059302A1 (de) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Faktor VIIa Inhibitore
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
WO2001016324A2 (en) * 1999-08-31 2001-03-08 Board Of Regents, The University Of Texas System Methods and compositions of a novel serine protease inhibitor
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
DE10029015A1 (de) * 2000-06-15 2001-12-20 Curacyte Ag Hemmstoffe für den Gerinnungsfaktor Xa
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
EP1358200A4 (de) 2000-10-06 2005-07-20 Xenoport Inc Von gallensäure abgeleitete verbindungen zur verbesserung der oralen absorption und systemischen bioverfügbarkeit von arzneistoffen
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
US6462021B1 (en) * 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002230836A1 (en) 2000-12-18 2002-07-01 Merck & Co., Inc. Benzylamine derivatives and their use as thrombin inhibitors
US6528503B2 (en) 2000-12-18 2003-03-04 Merck & Co., Inc. Thrombin inhibitors
CA2436176A1 (en) 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
DE10117730A1 (de) 2001-04-09 2002-10-10 Basf Ag Umsetzung von (Di)Aminen in Gegenwart einer Lysinoxidase und eines Reduktionsmittels
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
DE10133786A1 (de) * 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
SE0103590D0 (sv) 2001-10-26 2001-10-26 Astrazeneca Ab New Combination
SE0200198D0 (sv) 2002-01-23 2002-01-23 Astrazeneca Ab New use
EP1485345B1 (de) 2002-03-11 2008-06-25 Curacyte AG Hemmstoffe der urokinase, ihre herstellung und verwendung
DE10210590A1 (de) * 2002-03-11 2003-10-02 Curacyte Ag Hemmstoffe des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
US7084134B2 (en) 2002-05-02 2006-08-01 Merk & Co., Inc. Thrombin inhibitors
ATE414539T1 (de) * 2002-05-21 2008-12-15 Mayo Foundation Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
EP2982668A3 (de) 2002-12-03 2016-04-13 Pharmacyclics LLC 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidin-derivate als faktor viia inhibitoren zur behandlung von thromboembolischen erkrankungen
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0301879D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Ab New process
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
FR2867780B1 (fr) * 2004-03-19 2006-05-19 Servier Lab Nouveaux derives de 4-oxo-4,6,7,8-tetrahydropyrrolo (1,2-a) pyrazine-6-carboxamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1736465A4 (de) 2004-03-31 2009-06-17 Ajinomoto Kk Anilinderivative
US7795205B2 (en) 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
US7481787B2 (en) * 2005-02-14 2009-01-27 Optiscan Biomedical Corporation Fluid handling cassette having a spectroscopic sample cell
EP1879871A1 (de) * 2005-05-03 2008-01-23 Bayer CropScience S.A. Neue heterocyclylethylamid-derivate
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
WO2007103447A2 (en) * 2006-03-06 2007-09-13 Humagene, Inc. A method for the preparation of recombinant human thrombin
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
GB0807828D0 (en) * 2008-04-29 2008-06-04 Vantia Ltd Aminopyridine derivatives
CN102924567B (zh) * 2008-10-28 2014-06-04 上海医药工业研究院 一类肽化合物、其制备方法及用途
TWI419700B (zh) * 2010-01-06 2013-12-21 Academia Sinica 甘藷胰蛋白酶抑制因子用於治療發炎及痛敏感之用途
ES2483802T3 (es) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Inhibidores de serina proteasa
CN102464701B (zh) 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
WO2012075287A2 (en) * 2010-12-01 2012-06-07 The University Of Mississippi Novel selective inhibitors of prolylcarboxypeptidase
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CA3099753A1 (en) * 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
KR20220110531A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
AU2020395306A1 (en) 2019-12-04 2022-06-30 Omeros Corporation MASP-2 inhibitors and methods of use
IL293550A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
IL293551A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2748295A1 (de) * 1977-10-27 1979-05-03 Bayer Ag Neue derivate des bpti
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
US4568636A (en) * 1981-03-25 1986-02-04 Pentapharm Ag Tripeptide derivatives
US4395401A (en) * 1981-09-09 1983-07-26 Smithkline Beckman Corporation Renally active dipeptides
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
DE3505555A1 (de) * 1985-02-18 1986-09-11 Behringwerke Ag, 3550 Marburg Neue oligopeptidylargininolderivate und deren homologe, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel
PT84170B (pt) * 1986-01-24 1989-03-30 Sanofi Sa Processo para a preparacao de derivados n alfa-substituidos das n alfa-aril-sulfonilaminoacil d-amidinofenil-alaninamidas
DE3606480A1 (de) * 1986-02-28 1987-09-03 Behringwerke Ag Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (de) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV Protease-Hemmer
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5273982A (en) * 1990-03-09 1993-12-28 Hoffmann-La Roche Inc. Acetic acid derivatives
US5110812A (en) * 1990-06-04 1992-05-05 Bristol-Myers Squibb Co. Azetidin-2-one derivatives as serine protease inhibitors
US5037819A (en) * 1990-06-04 1991-08-06 Bristol-Myers Squibb Company Azetidin-2-one derivatives as serine protease inhibitors
TW201303B (de) 1990-07-05 1993-03-01 Hoffmann La Roche
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99538A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
IL99527A (en) * 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
JPH05503300A (ja) * 1990-11-15 1993-06-03 ペンタファルム　アクチェンゲゼルシャフト メタ置換フェニルアラニン誘導体
DE4115468A1 (de) * 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
CZ333492A3 (en) * 1991-11-12 1993-09-15 Lilly Co Eli Dipeptide of l-azetidine-2-carboxylic acids and l-argininaldehyde, process of its preparation and pharmaceutical preparation in which said dipeptide is comprised
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5780631A (en) * 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
AU1025795A (en) * 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
SE504185C2 (sv) * 1994-11-08 1996-12-02 Astra Ab Lagringsstabil vattenlösning för infusion av trombininhibitorer
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion

Also Published As

Publication number Publication date
JP2001322974A (ja) 2001-11-20
CZ290104B6 (cs) 2002-05-15
IS4166A (is) 1994-12-04
SI0701568T1 (en) 2001-08-31
MX9404114A (es) 1995-01-31
EP1067136A1 (de) 2001-01-10
ES2128277T1 (es) 1999-05-16
PL311819A1 (en) 1996-03-18
DE69427150T2 (de) 2001-09-06
CA2162900C (en) 2009-06-09
WO1994029336A1 (en) 1994-12-22
DE69427150D1 (de) 2001-05-31
DK0701568T3 (da) 2001-06-18
BR9406746A (pt) 1996-03-19
CN1099425C (zh) 2003-01-22
FI119812B (fi) 2009-03-31
PL181968B1 (pl) 2001-10-31
US5723444A (en) 1998-03-03
JP3205558B2 (ja) 2001-09-04
NL300178I2 (nl) 2005-10-03
ATE200783T1 (de) 2001-05-15
EP0701568A1 (de) 1996-03-20
DE122004000045I1 (de) 2005-04-21
HK1031375A1 (en) 2001-06-15
CA2162900A1 (en) 1994-12-22
FI955828A (fi) 1995-12-04
NO314406B1 (no) 2003-03-17
DE122004000045I2 (de) 2011-06-16
CN1278530A (zh) 2001-01-03
JP2002047264A (ja) 2002-02-12
US20050222395A1 (en) 2005-10-06
LU91173I2 (fr) 2005-07-11
NO954873D0 (no) 1995-11-30
SK283150B6 (sk) 2003-03-04
NL300178I1 (nl) 2005-05-02
NO954873L (no) 1996-02-01
IL109634A (en) 1999-04-11
KR100339456B1 (ko) 2002-12-06
MY119155A (en) 2005-04-30
IL123996A (en) 2008-07-08
US5602253A (en) 1997-02-11
RS49576B (sr) 2007-04-10
LT3768B (en) 1996-03-25
CN1178905C (zh) 2004-12-08
HU226825B1 (en) 2009-11-30
SG48013A1 (en) 1998-04-17
AU6986994A (en) 1995-01-03
AU684086B2 (en) 1997-12-04
SE9301916D0 (sv) 1993-06-03
CN1127509A (zh) 1996-07-24
SK145495A3 (en) 1996-10-02
EG20671A (en) 1999-11-30
NZ267534A (en) 1997-08-22
ES2128277T3 (es) 2001-07-01
US5939392A (en) 1999-08-17
NO2004009I1 (no) 2004-12-20
HU0103039D0 (en) 2001-09-28
EE03264B1 (et) 2000-04-17
LTIP1947A (en) 1994-12-27
FI955828A0 (fi) 1995-12-04
EP0701568B1 (de) 2001-04-25
UA65518C2 (en) 2004-04-15
YU33694A (sh) 1997-12-05
DE701568T1 (de) 1999-06-02
IS1805B (is) 2002-03-08
SA94150051B1 (ar) 2006-06-12
JPH08511018A (ja) 1996-11-19
PT701568E (pt) 2001-08-30
HRP940311A2 (en) 1996-10-31
CZ302095A3 (en) 1996-04-17
TW403731B (en) 2000-09-01
HU9503445D0 (en) 1996-01-29
RU2142469C1 (ru) 1999-12-10
IL109634A0 (en) 1994-08-26
HUT74739A (en) 1997-02-28
GR3036258T3 (en) 2001-10-31

Similar Documents

Publication Publication Date Title
EG20671A (en) New peptides derivatives
TW275615B (de)
HU9402480D0 (en) Aromatic carboxylic acid derivatives
FI862132A0 (fi) Cytostatiskt verksamma titanocenkomplex.
EP0470431A3 (en) Use of phosphomycin and the pharmaceutically acceptable salts thereof as a topical cicatrizer
CY2207B1 (en) Pharmaceutical for the treatment f skin disorders
IL89628A0 (en) Guanidinium compounds and their use as fungicides
IT1251202B (it) 6-amminochinoloni, sintesi ed impiego come antibatterici
GR3004354T3 (de)
DE69003029D1 (de) Terpenderivate, ihre Herstellung und Verwendung.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: ASTRAZENECA AB, SE

B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20100512

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20110518